OFFICIAL

IN THE CLAIMS

1. (currently amended) A compound ~~as represented by~~ of formula (I), or ~~its~~an enantiomers or diastereoisomers thereof:



(I)

wherein:

A is a 5- or 6-membered homocyclic ring~~, or a 5- or 6-membered heterocyclic ring containing 1 or more heteroatoms selected from N, O and S~~;

X is H and W is OH; or X and W together form a carbonyl group or an epoxide;

R^1 is H; or one or two substituents independently selected from the group consisting of: hydroxy; halo; lower alkyl; lower alkoxy; lower thioalkyl; haloalkyl (e.g. trifluoromethyl); or $-C(O)R^2$ wherein R^2 is lower alkyl, aryloxy or benzyloxy;

Y is phenyl optionally mono- or di-substituted with R^5 or $C(O)R^6$, wherein R^5 is lower alkyl, lower cycloalkyl, lower alkoxy, halo, hydroxy, nitrile or trifluoromethyl, and R^6 is lower alkyl, lower cycloalkyl, lower alkoxy, hydroxy or trifluoromethyl; said phenyl ring being optionally fused with a saturated or unsaturated 4 to 6-membered ring optionally containing a heteroatom selected from N, O and S;

~~or Y is a heterocycle (Het) containing one or more heteroatom selected from N, O or S, said Het optionally mono- or di-substituted with R^5 or $C(O)R^6$, wherein R^5 and R^6 are as defined above; said Het being optionally fused with a saturated or unsaturated 4 to 6-membered ring optionally containing a heteroatom selected from N, O and S;~~

or Y is ethylene-phenyl, said ethylene moiety being optionally mono-substituted with lower alkyl, wherein said phenyl ring is optionally mono- or di-substituted with R^5 or $C(O)R^6$, wherein R^5 and R^6 are as defined above; said phenyl ring being optionally fused with a saturated or unsaturated 4 to 6-membered ring optionally containing a heteroatom selected

from N, O and S;

~~or Y is ethylene Het, said ethylene moiety being optionally mono-substituted with lower alkyl, wherein Het is optionally mono- or di-substituted with R^5 or $C(O)R^6$, wherein R^5 and R^6 are as defined above; said Het being optionally fused with a saturated or unsaturated 4 to 6-membered ring optionally containing a heteroatom selected from N, O and S;~~

R^3 is selected from the group consisting of: ~~lower alkyl, lower cycloalkyl, lower alkylene,~~ aryl or lower aralkyl, ~~all of which optionally~~ mono- or di-substituted with:

~~lower alkyl, lower cycloalkyl, haloalkyl, halo, CN, azido, lower alkoxy, (lower alkyl)acyl, C_{1-6} thioalkyl, C_{1-6} alkylsulfonyl, NHC(O) lower alkyl, NHC(O) aryl, NHC(O) O lower alkyl, NHC(O)O aryl, aryl, aryloxy, hydroxy, nitro, amino, or~~ Het, said Het optionally mono- or di-substituted with lower alkyl, lower cycloalkyl, lower alkoxy, halo, hydroxy, nitrile, trifluoromethyl, $C(O)R^6$ wherein R^6 is as defined above;

said ~~lower cycloalkyl, aryl, lower aralkyl or~~ Het being optionally fused with a saturated or unsaturated 4 to 6-membered ring optionally containing a heteroatom selected from N, O and S;

and

R^4 is a carboxylic acid, a salt or an ester thereof;

~~and with the provises that:~~

~~(1) when A is benzene, R^1 is hydrogen, X and W together form a carbonyl group and Y is 4-methylphenyl, then R^3 cannot be benzyl, 3-fluorophenyl, or 4-nitrophenyl;~~

~~(2) when A is benzene, R^1 is hydrogen, X and W together form a carbonyl group and R^3 is cyclohexyl, then Y cannot be 4-iodophenyl or 4-methylphenyl;~~

~~(3) when A is benzene, R^1 is hydrogen, X and W together form a carbonyl group and Y is 4-fluorophenyl, then R^3 cannot be 4-ethyloxycarbonylphenyl;~~

~~(4) when A is benzene, R^1 is hydrogen, X and W together form a carbonyl group and Y is 2-methylphenyl then R^3 cannot be 4-nitrophenyl;~~

~~(5) when A is benzene, R^1 is hydrogen, X and W together form a carbonyl group and Y is 2-methylphenyl, then R^3 cannot be phenyl or 2-bromo-4-methylphenyl;~~

~~(6) when A is benzene, R^1 is hydrogen, X and W together form a carbonyl group and Y is 4-chlorophenyl, then R^3 cannot be 2-methoxyphenyl or 1,3-benzodioxolyl;~~

OFFICIAL

~~(7) when A is benzene, R^1 is hydrogen, X and W together form a carbonyl group and Y is 4-ethylphenyl, then R^3 cannot be 3-fluorophenyl; and~~

~~(8) when A is benzene, R^1 is hydrogen, X and W together form a carbonyl group and Y is phenyl, then R^3 cannot be phenyl.~~

2. (currently amended) A compound selected from ~~the group, consisting of~~:


(Ia),


(Ib),


(Ic),


(Id),


(Ie),


(If),


(Ig), and


(Ih),

wherein A, X, R^1, Y, R^3, and R^4 are as defined in claim 1~~, with the provisos indicated in claim 1~~.

3. (original) A mixture of compound I(a) and compound I(b), according to claim 2.

OFFICIAL

4. (original) A mixture of compound I(c) and compound I(d), according to claim 2.

5. (currently amended) A compound mixture ~~of,~~ according to claim 3, wherein said mixture is racemic.

6. (currently amended) A compound mixture ~~of,~~ according to claim 4, wherein said mixture is racemic.

7. (currently amended) ~~The compound I(a) and the compound I(b),~~ A compound I(a) according to claim ~~3~~2, ~~are each~~ as a pure enantiomer~~s~~.

8. (currently amended) ~~The compound I(c) and the compound I(d),~~ A compound I(c) according to claim 42, ~~are each~~ as a pure enantiomers.

9. (original) A compound according to claim 1 wherein X is H and W is OH; or X and W form a carbonyl group.

10. (original) A compound according to claim 9 wherein X and W form a carbonyl group.

11. (currently amended) A compound according to claim 1 wherein ring A is a benzene ring, as represented by the formula I':



I'

wherein X, R^1, W, Y, R^3, and R^4 are as defined in claim 1~~, with the provises indicated in claim 1~~.

12. (cancelled)

13. (original) A compound according to claim 1, wherein R^1 is H; or one or two substituents independently selected from the group consisting of: hydroxy; halo; lower alkyl; lower alkoxy; lower thioalkyl; haloalkyl; or $-C(O)R^2$ wherein R^2 is lower alkyl, aryloxy or benzyloxy.

14. (original) A compound according to claim 13, wherein R^1 is H, halo or C_{1-4} alkyl.

15. (original) A compound according to claim 14, wherein R^1 is H, fluoro or methyl.

16. (original) A compound according to claim 15, wherein R^1 is H or methyl.

17. (original) A compound according to claim 1, wherein Y is phenyl optionally mono- or di-substituted with R^5 or $C(O)R^6$, wherein R^5 is lower alkyl, lower cycloalkyl, lower alkoxy, halo, hydroxy, nitrile or trifluoromethyl, and R^6 is lower alkyl, lower cycloalkyl, lower alkoxy, hydroxy or trifluoromethyl; said phenyl ring being optionally fused with a saturated or unsaturated 4 to 6-membered ring optionally containing a heteroatom selected from N, O and S; or Y is ethylene-phenyl, said ethylene moiety being optionally mono-substituted with lower alkyl, wherein said phenyl ring is optionally mono- or di-substituted with R^5 or $C(O)R^6$, wherein R^5 and R^6 are as defined above; said phenyl ring being optionally fused with a saturated or unsaturated 4- to 6-membered ring optionally containing a heteroatom selected from N, O and S.

18. (original) A compound according to claim 17, wherein Y is naphthyl, CH=CH-phenyl, $C(CH_3)$=CH-phenyl or phenyl, wherein the phenyl ring is optionally mono- or di-substituted at the 3, 4, or 5 position with R^5, wherein R^5 is halo, C_{1-4} alkyl, hydroxy , CF_3 or NHC(O)-(lower alkyl).

19. (original) A compound according to claim 18, wherein Y is phenyl optionally substituted with: 3,4-Cl; 3-F,4-Cl; 3-Cl,4-F; 3,4-Br; 3-F,4-CH_3; 3,4-CH_3; 3-CF_3, $NHC(O)-(CH_2)_3CH_3$ and  .

20. (original) A compound according to claim 19, wherein Y is phenyl optionally substituted with: 3,4-Cl and 3,4-Br.

21. (currently amended) A compound according to claim 1, wherein R^3 is ~~selected from the group consisting of~~:

~~cyclohexyl; C_{1-6} alkyl; C_{1-6} thioalkyl;~~ (C_{1-6} alkyl)phenyl wherein the phenyl ring is optionally substituted with:

~~lower alkyl, CF_3, halo, CN, azido, lower alkoxy, (lower alkyl)acyl, C_{1-6} thioalkyl, C_{1-6} alkylsulfonyl, NHC(O)-lower alkyl, aryl, aryloxy, hydroxy, nitro, amino, or~~ Het, said Het optionally mono- or di-substituted with lower alkyl, lower alkoxy, halo, hydroxy, nitrile, or trifluoromethyl;

 ~~; and~~ .

22. (currently amended) A compound according to claim 21, wherein R^3 is selected from ~~the group consisting of~~:

~~C_{1-6} alkyl; C_{1-6} thioalkyl;~~





; and

; ~~and~~

23. (cancelled)

24. (cancelled)

25. (currently amended) A compound selected from the group consisting of: compounds having the following formula:



, wherein R^{4A}, R^1, R^5 and R^3 are as defined as follows:

Cpd #	R^{4A}	R^1	$-R^5$	$-R^3$

OFFICIAL

Cpd #	R^{4A}	R^1	$-R^5$	$-R^3$	
~~1002~~	~~Na~~	–	~~3,4-Cl~~		;
~~1003~~	~~Na~~	–	~~4-Cl~~		;
~~1004~~	~~Na~~	–	~~4-Cl~~		;
~~1005~~	~~Na~~	–	~~4-Cl~~		;
~~1006~~	~~Na~~	–	~~4-Cl~~		;
~~1007~~	~~Na~~	–	~~4-Cl~~		;
~~1008~~	~~Na~~	–	~~4-iPr~~		;
~~1009~~	~~Na~~	–	~~4-Cl~~		;
~~1010~~	~~Na~~	–	~~4-Cl~~		;
~~1011~~	~~Na~~	–	~~4-Cl~~		;
~~1012~~	~~Na~~	–	~~4-Cl~~		;
~~1013~~	~~Na~~	–	~~4-Cl~~		;
~~1014~~	~~Na~~	–	~~4-Cl~~		;
~~1015~~	~~Na~~	–	~~3-Cl~~		;
~~1016~~	~~Na~~	–	~~4-CF_3~~		;
~~1017~~	~~CH_3~~	–	~~4-Cl~~		;

OFFICIAL

Cpd #	R^{4A}	R^1	$-R^5$	$--R^3$
~~1018~~	~~Na~~	–	~~3-CH_3~~	 ;
~~1019~~	~~Na~~	~~a-F~~	~~4-Cl~~	 ;
~~1020~~	~~Na~~	–	~~3,5-Cl~~	 ;
~~1021~~	~~Na~~	–	~~3,4-Cl~~	 ;
~~1022~~	~~CH_3~~	–	~~3,4-Cl~~	 ;
~~1023~~	~~Na~~	–	~~3-OCH_3~~	 ;
~~1024~~	~~Na~~	–	~~3,4-CH_3~~	 ;
~~1025~~	~~Na~~	–	~~3,4-Cl~~	 ;
~~1026~~	~~Na~~	–	~~3,4-F~~	 ;
~~1027~~	~~Na~~	–	~~3,4-Br~~	 ;
1028	Na	--	3,4-Cl	 ;
~~1029~~	~~Na~~	–	~~3-F, 4-Cl~~	 ;
~~1030~~	~~Na~~	–	~~3-Cl, 4-F~~	 ;
~~1031~~	~~Na~~	–	~~3-CF_3~~	 ;

OFFICIAL

Cpd #	R^{4A}	R^1	$-R^5$	$-R^3$
~~1032~~	~~Na~~	–	~~3-Cl~~	 ;
~~1033~~	~~Na~~	–	~~3,4-Cl~~	 ;
1034	Na	--	3,4-Cl	 ;
~~1035~~	~~Na~~	–	~~3,4-Cl~~	 ;
~~1036~~	~~Na~~	–	~~3,4-Cl~~	 ;
~~1037~~	~~Na~~	~~b-CH_3~~	~~3,4-Cl~~	 ;
~~1038~~	~~Na~~	–	~~3,4-Cl~~	 ;
~~1039~~	~~Na~~	–	~~4-I~~	 ;
~~1040~~	~~Na~~	–	~~3,4-Cl~~	 ;
~~1041~~	~~Na~~	~~d-CH_3~~	~~3,4-Cl~~	 ;
~~1042~~	~~Na~~	~~a-CH_3~~	~~3,4-Cl~~	 ;
~~1043~~	~~Na~~	–	~~3,4-Cl~~	 ;
~~1044~~	~~Na~~	--	~~3-Cl~~	 ;
~~1045~~	~~Na~~	–	~~3-F, 4-CF_3~~	 ;
~~1046~~	~~Na~~	–	~~3,4-Cl~~	 ;

Cpd #	R^{4A}	R^1	$-R^5$	$-R^3$	
~~1047~~	~~Na~~	–	~~3,4-Cl~~		;
~~1048~~	~~Na~~	~~d-F~~	~~3,4-Cl~~		;
~~1049~~	~~Na~~	–	~~3,4-Cl~~		;
~~1050~~	~~Na~~	–	~~3,4-Cl~~		;
~~1051~~	~~Na~~	~~a-F~~	~~3,4-Cl~~		;
1052	Na	--	3,4-Cl		;
~~1053~~	~~Na~~	–	~~3,4-Cl~~		;
~~1054~~	~~Na~~	–	~~3,4-Cl~~		;
~~1055~~	~~Na~~	–	~~3,4-Cl~~		;
~~1056~~	~~Na~~	–	~~3,4-CH_3~~		;
~~1057~~	~~Na~~	–	~~3,4-Cl~~		;
~~1058~~	~~Na~~	–	~~3,4-Cl~~		;
1059	Na	--	3,4-F		;
~~1060~~	~~Na~~	–	~~3,4-Cl~~		;
~~1061~~	~~Na~~	–	~~3,4-F~~		;
~~1062~~	~~Na~~	–	~~3,4-F~~		;

OFFICIAL

Cpd #	R^{4X}	R^1	$-R^5$	$-R^3$	
~~1063~~	~~Na~~	—	~~3,4-Cl~~		~~÷~~
~~1064~~	~~Na~~	—	~~3,4-F~~		~~÷~~
~~1065~~	~~Na~~	—	~~3,4-Cl~~		~~÷~~
~~1066~~	~~Na~~	—	~~3,4-Cl~~		~~÷~~
~~1067~~	~~Na~~	—	~~3-F, 4-CF_3~~		~~÷~~
~~1068~~	~~Na~~	—	~~3,4-F~~		~~÷~~
~~1069~~	~~Na~~	~~b-Br~~	~~3,4-Cl~~		~~÷~~
~~1070~~	~~Na~~	—	~~3,4-Cl~~		~~÷~~
~~1071~~	~~Na~~	—	~~3,4-CH_3~~		~~÷~~
~~1072~~	~~Na~~	—	~~3,4-Br~~		~~÷~~
~~1073~~	~~Na~~	—	~~3,4-F~~		~~÷~~
~~1074~~	~~Na~~	—	~~3,4-Br~~		~~÷~~
~~1075~~	~~Na~~	—	~~3,4-Br~~		~~÷~~
1076	Na	--	3,4-Br		;
~~1077~~	~~Na~~	—	~~3,4-Cl~~		~~÷~~
1078	Na	--	3,4-Br		;
~~1079~~	~~Na~~	—	~~3,4-Br~~		~~÷~~

OFFICIAL

Cpd #	R^{4A}	R^1	$-R^5$	$-R^3$	
~~1080~~	~~Na~~	—	~~3-CN~~		÷
~~1081~~	~~Na~~	—	~~3,4-Br~~		÷
~~1082~~	~~Na~~	—	~~3,4-Cl~~		÷
1083	Na	—	3,4-F		;
~~1084~~	~~Na~~	—	~~3,4-Br~~		÷
1085	Na	—	3-CN		;
~~1086~~	~~Na~~	—	~~3,4-Br~~		÷
~~1087~~	~~Na~~	—			÷
~~1088~~	~~Na~~	—	~~3,4-Br~~	 ~~stereochemistry undetermined~~	÷
~~1089~~	~~Na~~	—	~~3,4-Br~~	 ~~stereochemistry undetermined~~	÷
~~1090~~	~~Na~~		~~3,4-Cl~~		÷
~~1091~~	~~Na~~		~~3,4-Cl~~		÷
~~1092~~	~~Na~~	—	~~3,4-Br~~		÷
~~1093~~	~~Na~~	—	~~3-Cl, 4-F~~		÷

OFFICIAL

Cpd #	R^{4A}	R^1	$-R^5$	$-R^3$	
~~1094~~	~~Na~~	–	~~3-Cl, 4-F~~		÷
~~1095~~	~~Na~~		~~3,4-Cl~~		÷
~~1096~~	~~Na~~	–	~~3,4-Cl~~		÷
~~1097~~	~~Na~~	–	~~3,4-Br~~		÷
~~1098~~	~~Na~~	–	~~3,4-Cl~~		÷
~~1099~~	~~Na~~	–	~~3,4-Br~~		÷
~~1100~~	~~Na~~	–	~~3,4-Cl~~		÷
~~1101~~	~~Na~~	–	~~3,4-Cl~~		÷
~~1102~~	~~Na~~	–	~~3,4-Br~~		÷
~~1103~~	~~Na~~	–	~~3,4-Br~~		÷
~~1104~~	~~Na~~	–	~~3,4-Cl~~		÷
~~1105~~	~~Na~~	–	~~3,4-Br~~		÷
~~1106~~	~~Na~~	~~b-F~~	~~3,4-Cl~~		÷
~~1107~~	~~Na~~	~~c-F~~	~~3,4-Cl~~		÷

OFFICIAL

Cpd #	R^{4A}	R^1	$-R^3$	$--R^3$	
~~1108~~	~~Na~~	—	~~3,4-Cl~~		÷
~~1109~~	~~Na~~	—	~~3,4-Br~~		÷
~~1110~~	~~Na~~	—	~~3,4-Br~~		÷
~~1111~~	~~Na~~	—	~~3,4-Cl~~		÷
~~1112~~	~~Na~~	—	~~3,4-Cl~~		÷
~~1113~~	~~Na~~	—	~~3,4-Br~~		÷
~~1114~~	~~Na~~	~~o-Cl~~	~~3,4-Cl~~		÷
~~1115~~	~~Na~~	—	~~3-Cl,4-F~~		÷
~~1116~~	~~Na~~	~~b-Cl~~	~~3,4-Cl~~		÷
~~1117~~	~~Na~~	—	~~3,4-Cl~~		÷
~~1118~~	~~Na~~	—	~~3,4-Br~~		÷
~~1119~~	~~Na~~	—	~~3,4-Br~~		÷
~~1120~~	~~Na~~	—	~~3-Cl,4-F~~		÷

OFFICIAL

Cpd #	R^{4A}	R^1	$-R^3$	$-R^3$	
~~1121~~	~~Na~~	–	~~3-Cl, 4-F~~		÷
~~1122~~	~~Na~~	–	~~3-Cl, 4-F~~		÷
~~1123~~	~~Na~~	–	~~3,4-Cl~~		÷
~~1124~~	~~Na~~	–	~~3,4-Cl~~		÷
~~1125~~	~~Na~~	–	~~3,4-Cl~~		÷
~~1126~~	~~Na~~	–	~~3,4-Cl~~		÷
~~1127~~	~~Na~~	–	~~3,4-Cl~~		÷
1128	Na	–	3,4-Cl		÷
~~1129~~	~~Na~~	~~o-OMe~~	~~3,4-Cl~~		÷
~~1130~~	~~Na~~	~~b-OMe~~	~~3,4-Cl~~		÷
~~1131~~	~~Na~~	–	~~3-Cl, 4-F~~		÷
~~1132~~	~~Na~~	–	~~3,4-F~~		÷
~~1133~~	~~Na~~	–	~~3,4-Cl~~		÷
~~1134~~	~~Na~~	–	~~3,4-Br~~		÷

Cpd #	R^{4A}	R^1	$--R^3$	$--R^3$	
~~1135~~	~~Na~~	–	~~3,4-Cl~~		;
~~1136~~	~~Na~~	–	~~3,4-Cl~~		;
~~1137~~	~~Na~~	–	~~3,4-Cl~~		;
~~1138~~	~~Na~~	–	~~3,4-Cl~~		;
~~1139~~	~~Na~~	–	~~3,4-Cl~~		;
~~1140~~	~~Na~~	–	~~3,4-Cl~~		;
~~1141~~	~~Na~~	–	~~3-NHC(O)(CH$_2$)$_2$CH$_3$; 4-Cl~~		;
~~1142~~	~~Na~~	–	~~3,5-Cl~~		;
1143	Na	b-F	3,4-Br		; and
1144	Na	c-F	3,4-Br		.

26. (currently amended) A compound selected from the group consisting of: compounds having the following formula:



wherein R^{4A}, R^1, R^5, and R^3 are as defined as follows:

Cpd #	R^{4A}	R^1	$-R^5$	$-R^3$	
A1001	Na	--	3,4-Br	 stereochemistry undetermined	;
A1002	Na	--	3,4-Br	 stereochemistry undetermined	;
~~A1003~~	~~Na~~	~~mixture b-Me & c-Me~~	~~3,4-Cl~~	 ~~stereochemistry undetermined~~	;
~~A1004~~	~~Na~~	~~b-Me~~	~~3,4-Cl~~	 ~~stereochemistry undetermined~~	;
~~A1005~~	~~Na~~	~~c-Me~~	~~3,4-Cl~~	 ~~stereochemistry undetermined~~	;
A1006	Na	mixture b-Me & c-Me	3,4-Cl	 stereochemistry undetermined	;

Cpd #	R^{4A}	R^1	$--R^5$	$--R^3$	
A1007	Na	b-Me	3,4-Cl	 stereochemistry undetermined	;
A1008	Na	c-Me	3,4-Cl	 stereochemistry undetermined	;
A1009	Na	mixture b-Me & c-Me	3,4-Br	 stereochemistry undetermined	;
A1010	Na	b-Me	3,4-Br	 stereochemistry undetermined	;
A1011	Na	c-Me	3,4-Br	 stereochemistry undetermined	;
A1012	Na	--	3,4-Br	 stereochemistry undetermined	;
A1013	Na	--	3,4-Br	 stereochemistry undetermined	;
A1014	Na	c-Me	3,4-Br		;
A1015	Na	b-F, c-Me	3,4-Br		; and
A1016	Na	b-Me, c-F	3,4-Br		.

27. (currently amended) A compound selected from the group consisting of: compounds having the following formula:



wherein R^1, R^5, and R^3 are as defined as follows:

Cpd #	R^1	R^5	R^3	
B1001	b-Me, c-Me (mixture)	3,4-Br		;
B1002	b-Me	3,4-Br		;
B1003	c-Me	3,4-Br		;
~~B1004~~	~~b-Me~~	~~3,4-Br~~		;
~~B1005~~	~~c-Me~~	~~3,4-Br~~		;
~~B1006~~	~~b-Me~~	~~3,4-Br~~		;
~~B1007~~	~~c-Me~~	~~3,4-Br~~		; and
B1008	b-F, c-Me	3,4-Br		.

28. (cancelled)

29. (cancelled)

30. (currently amended) A compound selected from the group consisting of: compounds having the following formula:



wherein R^5 and R^3 are as defined as follows:

Cpd #	$-R^5$	$---R^5$	
~~2002~~	~~4-Cl~~		÷
~~2003~~	~~4-Cl~~		÷
~~2004~~	~~4-Cl~~		÷
~~2005~~	~~3-Cl~~		÷
~~2006~~	~~4-Cl~~		÷
~~2007~~	~~4-Cl~~		÷
~~2008~~	~~4-CF_3~~		÷
~~2009~~	~~4-Cl~~		÷
~~2010~~	~~4-Cl~~		÷
~~2011~~	~~4-Cl~~		÷

OFFICIAL

Cpd #	--R^5	—R^3	
~~2012~~	~~4-Cl~~		÷
~~2013~~	~~3,4-Cl~~		÷
~~2014~~	~~3-CH_3~~		÷
~~2015~~	~~4-Cl~~		÷
~~2016~~	~~3,4-Cl~~		÷
~~2017~~	~~4-I~~		÷
~~2018~~	~~3,4-Cl~~		÷
~~2019~~	~~3,4-Cl~~		÷
~~2020~~	~~4-OH, 5-Cl~~		÷
~~2021~~	~~3,4-Cl~~		÷
~~2022~~	~~3,4-Cl~~		÷ ~~and~~
2023	3,4-Br		.

31. (currently amended) A compound selected from the group consisting of: compounds having the following formula:



wherein R^1, Y, and R^3 are as defined as follows:

Cpd #	R^1	--Y	$-R^3$	
~~3001~~	—			÷
~~3002~~	—			÷
~~3003~~	—			÷
~~3004~~	—			÷
~~3006~~	—			÷
~~3007~~	—			÷
~~3008~~	—			÷
~~3009~~	—			÷
~~3100~~	—			÷
~~3011~~	—			÷
~~3012~~	—			÷

Cpd #	R^1	–Y	$-R^3$
3013	c-Me		 ;
~~3014~~	–		 ;
~~3015~~	–		 ;
3016	b-F		 ; and
3017	c-F		 .

Claims 32-37 (cancelled)

38. (original) A compound having the following formula:



wherein Y and R^3 are as defined as follows:

Cpd #	–Y	$-R^3$
10,001		

39. (original) A pharmaceutical composition comprising an anti-papillomavirus virally effective amount of a compound of formula (I), according to claim 1, or a therapeutically acceptable salt or ester thereof, in admixture with a pharmaceutically acceptable carrier medium or auxiliary agent.

40. (currently amended) A method for treating a papillomavirus viral infection in a mammal by administering to the mammal an anti-papilloma virus virally effective amount of ~~the~~ a compound of formula (I), according to claim 1 ~~without the provisos indicated in claim 1~~, or a therapeutically acceptable salt or ester thereof, or a pharmaceutical composition comprising an anti-papillomavirus virally effective amount of a compound of formula (I) according to claim 1 ~~without the provisos indicated in claim 1~~, or a therapeutically acceptable salt or ester thereof, in admixture with a pharmaceutically acceptable carrier medium or auxiliary agent.

41. (currently amended) A method for inhibiting the replication of papillomavirus by exposing the virus to an amount of ~~the~~ a compounds of formula (I), according to claim 1 ~~without the provisos indicated in claim 1,~~ inhibiting the papilloma virus E1-E2-DNA complex, or a therapeutically acceptable salt or ester thereof, or a composition comprising an anti-papillomavirus virally effective amount of a compound of formula (I) according to claim 1 ~~without the provisos indicated in claim 1~~, or a therapeutically acceptable salt or ester thereof, in admixture with a pharmaceutically acceptable carrier medium or auxiliary agent.

42. (currently amended) A method of preventing perinatal transmission of HPV from mother to baby, by administering a compound of formula (I), according to claim 1, ~~without the provisos indicated in claim 1,~~ to the mother prior to giving birth.

Claims 43-53 (cancelled)

54. (new) A compound I(b) according to claim 2, as a pure enantiomer.

55. (new) A compound I(d) according to claim 2, as a pure enantiomer.